Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Lastest news posted on the gmed site:
FOR IMMEDIATE RELEASE
Contact:
David W. Moskowitz MD
CEO, GenoMed
Tel. 314.983.9933
dwmoskowitz@genomed.com
ST. LOUIS—March 6, 2009—GenoMed® (OTC Pink Sheets GMED.PK) announced today that it will be offering free medical consultations over the Internet.
Patients can reach GenoMed by entering the Skype ID of the company's CEO and Chief Medical Officer, David W. Moskowitz MD, MA(Oxon), FACP. His Skype ID is: dwmoskowitz.
During periods of light calling, GenoMed will be able to offer real-time video consultations via Skype.
Said Dr. Moskowitz, "Now that we're in a global recession, and 50 million Americans have no health insurance, it's time for us to help each other. Beginning immediately, GenoMed will be offering free medical consultations, especially for chronic diseases."
Dr. Moskowitz continued by saying, "Just as a heads-up. Our next goal is to find an insurance company somewhere in the world that's actually interested in having patients live longer, healthier lives outside of the hospital. No health insurance company wants to prevent disease--I've asked practically all of them over the past 7 years. Reinsurance companies are just as hopeless. But a catastrophic hospitalization company, or perhaps a life insurance company, might want to."
Dr. Moskowitz ended by saying, "Now we've got two of the three pieces we need for the nation's 50 million uninsured: cheap drugs which are already being offered by the big pharmacy chains, and Next Generation Disease Management for Baby Boomers, courtesy of GenoMed. Catastrophic hospitalization is the crucial third piece. When we have all three, we'll be able to avoid bankruptcy by healthcare."
About GenoMed
GenoMed published how to prevent 90% of kidney failure, and how to retard the progression of emphysema (COPD) in 2002. The company's "recipes" are the subject of pending patents, good in the US. GenoMed is now marketing its Next Generation Disease Management service globally to patients with diabetes, high blood pressure, or emphysema (COPD). Please contact GenoMed at www.genomed.com or www.thelatestmedicaltreatment.com, or call Dr. Moskowitz directly on Skype (ID = dwmoskowitz).
Safe Harbor Statement
This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) finances and treatments. The words or phrases "ought to," "should," "could," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors, and the possibility of our not being able to field all the calls we receive. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
youtube video:
nice, looks like things are coming together
stock looks a little better...i'm back in on the hopes that they actually do some pr this spring/summer season. guess we'll have to see what happens...
It will be interesting to see how this company does in the upcoming spring/summer season with everyone getting outdoors and exercising etc
I didn't see any end of day settlement trades yesterday...that could be a really good sign. We need more confirmation though. The beveage season is almost upon us. I've seen worse companies than this make big runs. Lets keep our fingers crossed.
you have to go to pinksheets.com and click on the filings tab to downloand the pdf file. I can't link to it directly because of the way pinksheets.com hosts its files.
it doesn't seem to be much by the way it trades...i guess we'll have to see how it plays out.
Stock chart: looks like we're at a nice support level here: http://stockcharts.com/charts/gallery.html?nspt
Shares outstanding per the last 10Q: 100,026,663
Company web site: http://www.newronsport.com/
This company has an interesting product...has anyone tried it?
more selling! Companies like this need true angel investors with deep pockets for them to work. The same old nonsense of issuing shares nonstop and diluting a stock to nothing really only provides companies with short-lived funding and destroys the shareholders in the process. such is life on the pink sheets. life is not easy for small companies, especially in this economy.
nice one!
NBRI gold stock news out
i don't think anyone has been paid - I am under the impression that he hasn't paid anyone in a long, long time for ir/pr from what I'm reading from the company's web site and his "Q&A" section. I'm hoping things change though with the company's stance on this because now the sector is hot. I think it warrants spending some money on some minimal pr work.
After years of stagnant funding, medical research in the United States is set for a big cash infusion that experts expect will boost work on a range of ailments as well studies involving human embryonic stem cells.
The $787 billion economic stimulus measure President Barack Obama signed on Tuesday includes $10 billion for the National Institutes of Health, with more than $8 billion of it to fund medical studies and the rest to upgrade research facilities.
Leaders in the research community said they expect money to go to scientists looking for better ways to treat cancer, heart disease, stroke, diabetes, Alzheimer's disease, obesity, arthritis, Parkinson's disease and other conditions.
"We have been working around the clock to prepare for this possibility, to make the most effective, transparent and immediate use of these extraordinary resources," acting NIH Director Dr. Raynard Kington said in an e-mail.
NIH funding is the lifeblood of much U.S. medical research. NIH funding was doubled from 1998 to 2003 in a push started during the Clinton administration, but stayed flat for the past six years under the Bush administration.
The new money, which advocacy groups say is largely due to Republican Senator Arlen Specter, comes on top of the NIH's normal funding of about $29 billion a year and will be spent over the next two years.
Kington said the NIH will favor grant applications that already have gone through the review process and have "a reasonable expectation of making progress in two years." The NIH has had no permanent leader since Dr. Elias Zerhouni resigned last year.
The advocacy group Research! America, whose members include research universities and hospitals as well as drug companies, said the money could create 70,000 jobs because it will flow to academic and research institutions across the country.
BACKLOG OF RESEARCH
"There is a backlog of approved, excellent research that NIH has not been able to fund. And the money will be spent now in order to get those projects up and running," Mary Woolley, the group's president, said in a telephone interview.
any decent stem cell news on this stock sends it through the roof imo. tight float on this one
ya all buys almost...looks like she's ready to bust out
jesus christ who keeps leaning on this stock? great things going on with the company, but a floundering stock
MDFI obama healthcare play ready to bust out
nice to see assay updates...the numbers continue to look good. I'm pleased.
looks like this is a good obama medical play
MDFI obama medical play
gettin some mojo
looks like more accumulation going on today...i think once obama starts talking about personalized medicine, we'll see this stock get some interest imo.
OT: I'm not a premium subscriber, so if someone PMs me they need to include their email adress for me so that I may reply.
NEWS: GenoMed's Results Supported by Canadian Study: Dose is Key!
FOR IMMEDIATE RELEASE
Contact:
David W. Moskowitz MD
CEO, GenoMed
Tel. 314.983.9938
dwmoskowitz@genomed.com
ST. LOUIS—February 12, 2009—GenoMed® (OTC Pink Sheets GMED.PK) announced today that AstraZeneca's study showing that high dose Atacand was better than low dose drug for patients with kidney failure fully supports results its CEO observed 15 years earlier.
Yesterday, AstraZeneca released results from a study using high dose Atacand (candesartan) in patients spilling protein in their urine (http://news.yahoo.com/s/nm/20090211/hl_nm/us_kidney_disease_2). Although the patients were unresponsive to 16 mg a day, they responded well to a dose 8 times greater, 128 mg a day.
GenoMed's CEO, David Moskowitz MD, noticed a similar phenomenon beginning in 1994. Patients who progressed rapidly to dialysis on the conventional dose of ACE inhibitor reversed their kidney failure when the dose was increased sufficiently. The only dose-dependent side effect, high serum potassium, could be easily controlled using a second medication. Not all ACE inhibitor drugs were equivalent, however, and ARBs added little.
Dr. Moskowitz published these results in 2002. They form the basis for GenoMed's Next Generation Disease Management service for patients with diabetes or high blood pressure.
Said Dr. Moskowitz, "It's been over six years since we published our results in a peer-reviewed journal. We could have kept 90% of America's current 300,000 dialysis and transplant patients out of trouble if our paper had received the slightest press attention. The healthcare system's ongoing failure to embrace a cure that affects tens of millions of people is a public health tragedy of global proportions. My only conclusion is that disease itself has become too lucrative for the healthcare system to allow its elimination. Any attempt to reform the healthcare system must take into account its fundamental corruption over the past half century."
About GenoMed
GenoMed published how to prevent 90% of kidney failure in 2002. The company's "recipe" is the subject of a pending patent, good in the US. GenoMed is now marketing its Next Generation Disease Management service globally to patients with diabetes or high blood pressure. Please contact GenoMed at www.genomed.com or www.thelatestmedicaltreatment.com.
Safe Harbor Statement
This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) finances and treatments. The words or phrases "ought to," "should," "could," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
Excerpt from Obama's introductory remarks to the Genomics and Personalized Medicine Act bill of 2007:
"We know that all human beings are 99.9 percent identical in genetic makeup, but differences in the remaining 0.1 percent hold important clues about the causes of disease and response to drugs. Simply put, the study of genomics will help us learn why some people get sick and others do not, and use this information to better prevent and treat
disease.
The relatively new field of genomics is key to the practice of personalized medicine. Personalized medicine is the use of genomic and molecular data to better target the delivery of health care, facilitate the discovery and clinical testing of new products, and help determine a patient'\'s predisposition to a particular disease or condition. Personalized medicine represents a revolutionary and exciting change in the fundamental approach and practice of medicine.
Pharmacogenomics, or the study of how genes affect a person's response to drugs, is a critical component of personalized medicine. Currently, so-called blockbuster drugs are typically effective in only 40 to 60 percent of patients who take them. Other studies have found that up to 15 percent of hospitalized patients experience a serious adverse drug reaction, causing an estimated 100,000 deaths each year. Pharmacogenomics has the potential to dramatically increase the effectiveness and safety of drugs, both of which are major health care concerns."
from:
www.geneticalliance.org/ksc_assets/publicpolicy/introductory_remarks_obama_s976.pdf
looks like DNAG and GMED had some association a while back....I bought into both of these.
http://www.thefreelibrary.com/GenoMed,+Inc.+Adds+Tony+Frudakis,+Ph.D.+to+Scientific+Advisory+Board-a080630842
good question, we need an expert in the field to really answer that question. in my opinion, the value is there because another company recently wanted to buy them out, but they couldn't raise the finanacing in a tough time.
20 million share s-8 just filed. snap!
gettin a little mojo
Full text of pr:
FOR IMMEDIATE RELEASE
Contact:
David W. Moskowitz MD
CEO, GenoMed
Tel. 314.983.9938
dwmoskowitz@genomed.com
ST. LOUIS—February 11, 2009—GenoMed® (OTC Pink Sheets GMED.PK) announced today that its CEO, David Moskowitz MD, will continue to market the company's Next Generation Disease Management service to the developing world, this time to Asia.
In two weeks, GenoMed's CEO will meet with public health authorities in Kuala Lumpur, Malaysia and Singapore to discuss preventive molecular medicine. The agenda will include how to reverse diabetic and hypertensive kidney failure, as well as delay the progression of emphysema.
The Malaysian National Health Service is responsible for 15 million citizens. Many have diabetes, and kidney failure is a growing problem.
Although Singapore is much smaller, it recently made a bid to become the world leader in biotechnology, having built "Biopolis," a biotech city, two years ago, and attracted leading scientists from the West to work in it.
Dr. Moskowitz will be in Malaysia to deliver a speech at a healthcare conference (http://www.scribd.com/doc/7975121/Malaysia-Healthcare). In his lecture, he will say that leadership in healthcare may be shifting from the First World to the developing world.
Dr. Moskowitz said, "Ironically, the developing world may profit first from advances in personalized medicine. Less infrastructure—fewer hospitals and dialysis units--actually turns out to be an advantage. There's less financial resistance to clinical innovation. And the Internet allows us to deliver preventive molecular medicine inexpensively anywhere around the globe."
Dr. Moskowitz will visit Biopolis in Singapore to discuss possible collaboration. Biopolis is already the sort of "virtual" pharmaceutical company that Dr. Moskowitz has predicted will replace Big Pharma. The recent purchase of Wyeth by Pfizer confirms the fact that Big Pharma is disappearing as an industry. A new business model will be required for drug discovery and development.
About GenoMed
GenoMed published how to prevent 90% of kidney failure in 2002. It is now marketing its Next Generation Disease Management service globally to patients with diabetes or high blood pressure. Please contact GenoMed at www.genomed.com or www.thelatestmedicaltreatment.com.
Safe Harbor Statement
This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) finances and treatments. The words or phrases "ought to," "should," "could," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
i think that will change imo, the industry is heating up and now is the time for the company to come back out into the open again. keeping my fingers crossed
yep, this company looks primed to me...from what it appears, the ceo is sharholder friendly...no major share issuances in a long time, promising intellectual property (witness what that did for ACTC - .03 to .29/share with way more shares outstanding), transparency (ungagged transfer agent), and obama is big on pushing for personalized medicine that will control healthcare costs. He spoke about this last night in his address to the nation actually. This company hits the sweet spot of saving money in healthcare because it helps identify variances within our genetic makeup which make us predisposed to certain diseases...also this leads to preventative medicine as well as properly prescribing drugs based on how our system reacts to certain drugs. i.e saving money instead of trial and error wasteful treatments. Also, its important to be able to predict which diseases we are gentically predisposed to so that we can treat them in advance...preventing disabling disases now rather than later saves money.
accumulation :)
still going.... .011 X .013
another mma company bites the dust..zheesh...looks like the ufc has the only business model that works
up, up we go...looks like more accumulation